Kiran Mazumdar Shaw- Founder & Chairperson, Biocon Group
If the 20th century was defined by energy security and the early 21st by digital sovereignty, the coming decades will be shaped by biotech sovereignty embedded in artificial intelligence. Nations that command the convergence of biology and AI will define the future of healthcare, food security, bio-manufacturing, and biosecurity. For India, this is not merely an opportunity, it is a strategic and geopolitical imperative.
Where Biology Meets Intelligence
Living systems are the original intelligent machines. Cells sense, compute, and respond through intricate signalling networks, gene regulation circuits, and immune memory. These systems operate within inbuilt biological guardrails which focus on feedback loops and control mechanisms that maintain homeostasis, or health equilibrium. Disease arises when these guardrails fail.
AI, by contrast, learns from data to optimise decisions at machine scale. The true inflection point lies at their intersection: AI-powered biology. From protein structure prediction and generative drug design to digital twins of cells and organs, AI is compressing discovery timelines and reducing development risk. The next frontier is even more profound, the reprogramming of cells themselves to restore biological balance.
Reprogramming Life: From Treatment to Re-Engineering
We are moving from static, one-size-fits-all drugs to programmable biology. AI-native platforms are enabling:
- Cancer therapies that reprogram immune cells (CAR-T, TCR-T, NK cells) to recognise and eliminate tumours with precision.
- Autoimmune disease interventions that recalibrate immune tolerance rather than broadly suppress immunity.
- Longevity and health span strategies that modulate senescence, metabolic pathways, and cellular repair mechanisms to delay biological ageing and restore tissue resilience.
Crucially, these approaches seek not to overpower biology but to reinforce its inbuilt guardrails which focus on repair, feedback control, and immune surveillance. AI can map these regulatory circuits at scale, enabling targeted interventions that preserve homeostasis. This represents a paradigm shift: from managing disease to re-engineering biological systems to sustain health.
Why Sovereignty in AI-Biotech Matters
India’s future health security will depend on who controls the code of life and the code of intelligence. If foundational AI models for drug discovery, genomics, cellular engineering, and clinical decision-making are owned offshore, India risks strategic dependence in the most critical domain of national resilience – human health.
Biotech sovereignty embedded in AI must therefore mean sovereign control over trusted biological data, indigenous AI models, compute infrastructure, and translational platforms, from discovery and development to manufacturing and delivery. This is essential not only for economic competitiveness but also for preparedness against pandemics, antimicrobial resistance, and emerging bio-threats.
From ‘Pharmacy’ to ‘Biotech Platform of the World’
India’s global role must evolve from being the ‘Pharmacy of the World’ to becoming the ‘Biotech Platform of the World’, a nation that offers AI-native discovery engines, programmable therapy platforms, and scalable bio-manufacturing as global public goods. This requires embedding AI across the biotech value chain:
- Discovery: Foundation models for proteins, RNA, cellular circuits, and systems biology
- Development: In-silico trials, digital twins, and AI-driven trial design to de-risk pipelines
- Manufacturing: Smart bio-manufacturing using AI for yield optimisation and quality-by-design
- Regulation: Science-first, tech-enabled regulatory pathways integrating real-world evidence and AI validation
- Delivery: AI-powered pharmacovigilance, personalised medicine, and population-scale health optimisation
Building the National Platform: The Triple Helix
This transformation cannot be driven by industry alone. It demands a triple helix of government, academia, and industry:
- Government must invest in sovereign AI–bio infrastructure, trusted data architectures, national compute, regulatory sandboxes, and mission-mode programs in cell and gene therapy, immuno-oncology, and longevity science.
- Academia must mainstream computational biology, neuro-symbolic AI, and AI-first life sciences education to build a new cadre of translational scientists.
- Industry must co-create shared platforms, translational pipelines, and globally benchmarked biomanufacturing clusters that convert science into scale.
Capital markets must also evolve to support long-cycle, high-risk biotech innovation. Deep science requires patient capital, but the societal and economic returns from reduced disease burden to global platform leadership are exponential.
Ethics, Trust, and Global Leadership
Sovereignty is not isolation. India must build ethical, transparent, energy-efficient, and bias-aware AI systems for biology that are globally interoperable yet rooted in public interest. By embedding principles of equity, affordability, and access into AI-driven biotech, India can offer the world a new model of innovation, combining technological leadership with social purpose.
The Strategic Moment
The convergence of biological intelligence and artificial intelligence is redefining power in the 21st century. The ability to reprogram cells to fight cancer, correct immune dysfunction, and extend healthy longevity, while respecting the body’s natural guardrails of homeostasis, will determine who leads the next era of medicine.
For India, biotech sovereignty embedded in AI is not a sectoral ambition; it is a foundation of health security, strategic autonomy, and economic resilience. Those who master the language of life, augmented by the language of machines, will shape the future of humanity. India has the science, the scale, and the values to lead provided it builds the sovereign platforms of tomorrow, today.
Kiran Mazumdar Shaw’s OpEd was published in The Economic Times : AI-biotech sovereignty will define India’s future
